Linkage of bovine erythrocyte antigen loci B, C, L, S, Z, R' and T' and the serum protein loci post-transferrin 2 (PTF 2), vitamin D binding protein (GC) and albumin (ALB) to DNA microsatellite markers

Seven bovine erythrocyte antigen loci and three serum protein loci were tentatively assigned to chromosomes or synteny groups by linkage analysis to previously assigned microsatellite DNA markers. The erythrocyte antigen locus EAB was mapped to synteny group U27; EAC to chromosome 18, synteny group U9; EAL to chromosome 3, synteny group U6; EAS to chromosome 21, synteny group U4; EAZ to chromosome 10, synteny group U5; EAR' to chromosome 16, synteny group U1; and EAT' to chromosome 19, synteny group U21. The vitamin D binding protein (GC) and albumin (ALB) loci were assigned to chromosome 6, synteny group U15 and post-transferrin 2 (PTF 2) to chromosome 19, synteny group U21.     

9. The algal flora of the Primorsky Region, Russian Far East

A survey of the freshwater algal flora of the Primorsky Region, Russian Far East, is presented. During more than 70 years of investigations 1659 species (including varieties and forms 2276 taxa) belonging to 346 genera of different groups of algae have been recorded from this territory. The Primorsky Region is rich in habitats attractive to algae-rivers, lakes, reservoirs, and ponds. The details of the distribution of algae in different types of waterbodies have been examined. The algal flora of the region is comparable to the areas, and its taxonomical structure is typical for Eurasia. From this territory some new species and varieties have been described — Achnanthes chankensis, Cymbella ventricosa var. hankensis, Surirella alisoviana, and others. The flora includes some rare species — Fragilaria magocsyi, Perone dimorpha, and Heterothrix monochloron, and some endemics of Asia — Navicula scutelloides var. baicalensis, N. globulifera var. nipponica, Gomphonema sphaerophorum, and Surirella tientsinensis.     

Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?

A recent meta-analysis from the Antiplatelet Trialists'' Collaboration recommended that antilatelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis should be considered for patients at high risk of thromboembolism. This paper argues that the current evidence does not justify the adoption of aspirin or other antiplatelet treatment for venous thromboprophylaxis, especially when more effective alternatives exist. Furthermore, several issues relating to this latest meta-analysis need to be debated.